IMR Press / EJGO / Volume 39 / Issue 1 / DOI: 10.12892/ejgo3763.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Role of lymphadenectomy and vincristine, actinomycin-D, and cyclophosphamide chemotherapy in malignant ovarian germ cell tumors
Show Less
1 Department of Obstetrics & Gynaecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
2 Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
Eur. J. Gynaecol. Oncol. 2018, 39(1), 63–69; https://doi.org/10.12892/ejgo3763.2018
Published: 10 February 2018
Abstract

Purpose of investigation: The objective of this study was to review all malignant ovarian germ cell tumors (MOGCT) managed at the present center, focusing on the role of lymphadenectomy, and vincristine, actinomycin-D, cyclophosphamide (VAC) chemotherapy on treatment, and survival outcome. Materials and Methods: The authors performed a retrospective chart review of 77 patients managed for MOGCT between January 1986 and December 2012. Results: Median age at diagnosis was 26 years. The histologic subtypes included 47 (61.0%) immature teratoma, 16 (20.8%) yolk sac tumor, 9 (11.7%) dysgerminoma, and five (6.5%) mixed germ cell tumor. Of 65 patients with clinically early-stage tumors, 17 (26.1%) had lymphadenectomy performed, of which all had no lymph node metastasis on histology. The overall survival was 100% for both lymphadenectomy and no lymphadenectomy groups. Postoperative adjuvant chemotherapy was administered to 51 (66.2%) patients, 38 (74.5%) of whom received VAC chemotherapy. Complete response and overall cure rate of VAC regimen was 100% and 89.5%, respectively when used as first-line postoperative adjuvant treatment. Median follow-up period was 138 months and overall survival was 97.4%. Conclusions: Lymphadenectomy did not provide survival benefits in patients with clinically earlystage MOGCT. The VAC chemotherapy regimen can be considered as an option for primary postoperative treatment, especially in patients with early-stage disease.
Keywords
Malignant ovarian germ cell tumors
Lymphadenectomy
Chemotherapy
Share
Back to top